SLC5A2 and chronic kidney disease: By contrast, a study demonstrated that SGLT2 inhibitors initially reduced glomerular filtration rate compared with the placebo group in the long term and this discovery underscores the substantial advantages of dapagliflozin for individuals with chronic kidney disease, regardless of their diabetic status.